Medical Journal of The Islamic Republic of Iran (MJIRI)

What is CrossMark?

CrossMark is a multi-publisher initiative from CrossRef that provides a reliable way to locate the authoritative version of a published document. For more information, please cosult the link below.

https://www.crossref.org/services/crossmark

Clicking on the CrossMark icon either appeared on the abstract page in the MJIRI website or on the PDF files will link the reader to the current status of the published document. Additional information will also be available upon DOI policy.

Using CrossMark

Medical Journal of the Islamic Republic of Iran (MJIRI) uses CrossMark icon to ensure readers that all possible changes of published documents will be notified immediately after the changes appeared in the MJIRI website (http://mjiri.iums.ac.ir). This is currently for articles published after 2017. Previous back issues will also be treated similarly upon the MJIRI policy for back issues.   

Permanency of Content

 In addition of the MJIRI Archive, all published materials are available from the journal Google Scholar page, PubMed Central (from 2014 on), and in Crossref’s DOI depository. Clicking on the CrossMark seal printed at the top of each article’s PDF and also in the abstract page will bring the readers latest status of the article and the latest published version.

MJIRI and Ethical issues

MJIRI is a COPE member and follows all related ethical guidelines for all accepted articles. However, the authors will be informed for any related concerns prior to decisive actions. We encourage authors to consult COPE guidelines prior to any submission to MJIRI. The MJIRI policy for corrections, errata, corrigenda and partial retractions is similar to that of MEDLINE so that all cases will be treated as Errata. The errata will be published at the end of due article under the name of errata. CrossMark will notify the change immediately after it gets published in the MJIRI main website (http://mjiri.iums.ac.ir).   

Retraction of articles in MJIRI is subject to clear evidence of misconduct. Other issues such as inconclusive results and incomplete or unreliable presentation of data will be negotiated with authors prior to any action. All issues will be discussed electronically (via email) with the corresponding author.